For the Inventor, By the Inventor

Enter assignee name

Westlake Village, CA, United States of America

Arcutis Biotherapeutics, Inc.

USPTO Granted Patents = 26

CIPO Patents = 9

EPO Patents = 3

Trademarks = 7

Forward Citations = 83

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

David W Osborne (25 out of 41 patents)

Babak N Tofig (4 out of 4 patents)

Patrick Eugene Burnett (2 out of 2 patents)

4. David Reuben Berk (2 out of 2 patents)

5. Archie W Thurston, Jr (1 out of 1 patent)

6. Bhaskar Chaudhuri (1 out of 6 patents)

7. Saori Kato (1 out of 1 patent)

8. Saori Kato (1 out of 1 patent)

9. Jason Michael Carbol (1 out of 1 patent)

10. Herbert R Brinkman (1 out of 1 patent)

11. Frank Watanabe (1 out of 1 patent)

12. Howard Welgus (1 out of 1 patent)

13. Saori Kato (0 patent)

26 patents: Sort by Forward Citations

1. 12458652 - Pharmaceutical compositions of spironolactone for deep dermal drug delivery (2025-11-04),

2. 12453721 - Topical roflumilast aerosol foams (2025-10-28),

3. 12390453 - Method for reducing side effects from administration of phosphodiesterase-4 inhibitors (2025-08-19),

4. 12336983 - Inhibition of crystal growth of roflumilast (2025-06-24),

5. 12329751 - Topical roflumilast formulation having antifungal properties (2025-06-17),

6. 12310956 - Topical roflumilast formulation having improved delivery and plasma half-life (2025-05-27),

7. 12257242 - Inhibition of crystal growth of roflumilast (2025-03-25),

8. 12220409 - Roflumilast formulations with an improved pharmacokinetic profile (2025-02-11),

9. 12161643 - Stable formulations of SHR0302 (2024-12-10),

10. 12144802 - Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug (2024-11-19),

11. 12083122 - Laureth-4 containing topical formulations (2024-09-10),

12. 12053481 - Compositions and methods for deep dermal drug delivery (2024-08-06),

13. 12042558 - Method and formulation for improving roflumilast skin penetration lag time (2024-07-23),

14. 12042487 - Method for reducing side effects from administration of phosphodiesterase-4 inhibitors (2024-07-23),

15. 12016848 - Roflumilast formulations with an improved pharmacokinetic profile (2024-06-25),

Arcutis Biotherapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for dermatological conditions. The company's pipeline includes treatments for psoriasis, eczema, and other dermatological disorders. Arcutis is committed to advancing dermatology research and improving the lives of patients with skin conditions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

26 Patents

#5 in Westlake Village, CA

#2,953 in California

#12,424 in US

#24,051 in the World

Westlake Village, CA, United States of America

Arcutis Biotherapeutics, Inc.

Forward Citations = 83

15 inventors:

David W Osborne (25 out of 41 patents)

Babak N Tofig (4 out of 4 patents)

Patrick Eugene Burnett (2 out of 2 patents)

4. David Reuben Berk (2 out of 2 patents)

5. Archie W Thurston, Jr (1 out of 1 patent)

Please report any incorrect information to support@idiyas.com

Loading…